Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Should l Buy IBRX?
Source: Newsfilter
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.380
Low
5.00
Averages
7.33
High
9.00
Current: 7.380
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IMMUNITYBIO INC PLANS TO FILE SUPPLEMENTAL BLA BY 2026
Community Bio Initiative: The initiative focuses on submitting supplemental information to enhance community engagement and support.
Contractual Framework: The project is structured under a contract that outlines the responsibilities and expectations for all parties involved.
Timeline for Submission: The goal is to have all supplemental materials submitted by the year 2026.
Impact on Local Development: The initiative aims to foster local development and improve community resources through collaborative efforts.
See More
IBRX Stock Rebounds: Anktiva Shifts Focus to Severe Pneumonia Following Successful Bladder Cancer Trial Milestone
Bladder Cancer Study Update: A Phase 3 bladder cancer study has reached a key efficacy endpoint, prompting a review by an independent monitoring committee. The trial is comparing a combination therapy of Anktiva and BCG against BCG alone in newly diagnosed patients.
Stock Performance: Shares of Immunity Bio (IBRX) surged by about 9% following the announcement of new trials and progress in their bladder cancer study, recovering from a previous sharp sell-off.
New Trials for Severe Pneumonia: Immunity Bio has initiated new studies evaluating Anktiva in combination with off-the-shelf immune cell therapy for critically ill patients with severe pneumonia, aiming to improve immune function and survival rates.
Market Sentiment: Retail sentiment for IBRX has shifted positively, with significant increases in message volumes, indicating growing investor interest and optimism about the company's potential in cancer therapies.
See More
Class Action Lawsuit Filed Against ImmunityBio, Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of ImmunityBio securities purchasers from January 19 to March 24, 2026, indicating significant legal risks that could impact the company's stock price and investor confidence.
- Compensation Structure: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket costs, a no-risk arrangement that could attract more affected investors and enhance the lawsuit's overall impact.
- False Statement Allegations: The lawsuit alleges that ImmunityBio executives made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, which, if proven true, could severely damage the company's reputation and future business prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, can seek lead plaintiff status by May 26, 2026, indicating significant investor concern over potential legal risks facing the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio and its Executive Chairman made false and misleading statements regarding the efficacy of its lead biologic product, Anktiva, which could lead to investor misjudgment about the company's future prospects.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter stating that ImmunityBio's advertising misbranded Anktiva, resulting in a 21% drop in stock price, reflecting the direct impact of regulatory risks on the company's market valuation.
- Law Firm's Strength: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strong capability and influence in handling similar cases.
See More
ImmunityBio Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has launched a class action against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, with a deadline for lead plaintiff motions set for May 26, 2026, indicating the urgency of legal recourse.
- Stock Price Plunge Impact: ImmunityBio's stock price plummeted by $0.89, or 12.13%, to close at $6.45 on January 23, 2026, directly affecting investor asset values and reflecting a pessimistic market outlook on the company's future.
- Poor Clinical Trial Results: The company's announcement on January 23 regarding the GBM immunotherapy trial failed to meet critical benchmarks, particularly the
See More
ImmunityBio Accused of Misleading Investors
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026, and March 25, 2026, indicating strong investor reaction to potential misleading actions by the company.
- FDA Warning Letter Exposed: According to the complaint, CEO Soon-Shiong was accused of overstating the capabilities of the lead product ANKTIVA, with the FDA warning letter on March 24, 2026, highlighting misleading claims that ANKTIVA could cure and prevent all cancers, leading to a loss of investor confidence.
- Significant Stock Price Drop: Following the FDA warning, ImmunityBio's stock plummeted by 21% on March 24, 2026, losing $1.98 per share to close at $7.42, reflecting a pessimistic market outlook on the company's future.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 26, 2026, demonstrating investor concern for corporate governance and transparency, which may influence future investment decisions.
See More
IMMUNITYBIO INC PLANS TO FILE SUPPLEMENTAL BLA BY 2026
Community Bio Initiative: The initiative focuses on submitting supplemental information to enhance community engagement and support.
Contractual Framework: The project is structured under a contract that outlines the responsibilities and expectations for all parties involved.
Timeline for Submission: The goal is to have all supplemental materials submitted by the year 2026.
Impact on Local Development: The initiative aims to foster local development and improve community resources through collaborative efforts.
See More
IBRX Stock Rebounds: Anktiva Shifts Focus to Severe Pneumonia Following Successful Bladder Cancer Trial Milestone
Bladder Cancer Study Update: A Phase 3 bladder cancer study has reached a key efficacy endpoint, prompting a review by an independent monitoring committee. The trial is comparing a combination therapy of Anktiva and BCG against BCG alone in newly diagnosed patients.
Stock Performance: Shares of Immunity Bio (IBRX) surged by about 9% following the announcement of new trials and progress in their bladder cancer study, recovering from a previous sharp sell-off.
New Trials for Severe Pneumonia: Immunity Bio has initiated new studies evaluating Anktiva in combination with off-the-shelf immune cell therapy for critically ill patients with severe pneumonia, aiming to improve immune function and survival rates.
Market Sentiment: Retail sentiment for IBRX has shifted positively, with significant increases in message volumes, indicating growing investor interest and optimism about the company's potential in cancer therapies.
See More
Class Action Lawsuit Filed Against ImmunityBio, Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of ImmunityBio securities purchasers from January 19 to March 24, 2026, indicating significant legal risks that could impact the company's stock price and investor confidence.
- Compensation Structure: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket costs, a no-risk arrangement that could attract more affected investors and enhance the lawsuit's overall impact.
- False Statement Allegations: The lawsuit alleges that ImmunityBio executives made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, which, if proven true, could severely damage the company's reputation and future business prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, can seek lead plaintiff status by May 26, 2026, indicating significant investor concern over potential legal risks facing the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio and its Executive Chairman made false and misleading statements regarding the efficacy of its lead biologic product, Anktiva, which could lead to investor misjudgment about the company's future prospects.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter stating that ImmunityBio's advertising misbranded Anktiva, resulting in a 21% drop in stock price, reflecting the direct impact of regulatory risks on the company's market valuation.
- Law Firm's Strength: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strong capability and influence in handling similar cases.
See More
ImmunityBio Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has launched a class action against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, with a deadline for lead plaintiff motions set for May 26, 2026, indicating the urgency of legal recourse.
- Stock Price Plunge Impact: ImmunityBio's stock price plummeted by $0.89, or 12.13%, to close at $6.45 on January 23, 2026, directly affecting investor asset values and reflecting a pessimistic market outlook on the company's future.
- Poor Clinical Trial Results: The company's announcement on January 23 regarding the GBM immunotherapy trial failed to meet critical benchmarks, particularly the
See More
ImmunityBio Accused of Misleading Investors
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026, and March 25, 2026, indicating strong investor reaction to potential misleading actions by the company.
- FDA Warning Letter Exposed: According to the complaint, CEO Soon-Shiong was accused of overstating the capabilities of the lead product ANKTIVA, with the FDA warning letter on March 24, 2026, highlighting misleading claims that ANKTIVA could cure and prevent all cancers, leading to a loss of investor confidence.
- Significant Stock Price Drop: Following the FDA warning, ImmunityBio's stock plummeted by 21% on March 24, 2026, losing $1.98 per share to close at $7.42, reflecting a pessimistic market outlook on the company's future.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 26, 2026, demonstrating investor concern for corporate governance and transparency, which may influence future investment decisions.
See More
